Identification

Name
Tranylcypromine
Accession Number
DB00752  (APRD00645)
Type
Small Molecule
Groups
Approved
Description

A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311).

Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).

Structure
Thumb
Synonyms
  • (±)-trans-2-phenylcyclopropylamine
  • (1R*,2S*)-2-phenylcyclopropan-1-amine
  • DL-tranylcypromine
  • Racemic Tranylcypromine
  • Tranilcipromina
  • trans-2-phenylcyclopropylamine
  • trans-DL-2-Phenylcyclopropylamine
  • Transamine
  • Tranylcypromin
  • Tranylcypromine
  • Tranylcyprominum
External IDs
SKF 385 / SKF Trans-385
Product Ingredients
IngredientUNIICASInChI Key
Tranylcypromine sulfate7ZAT6ES87013492-01-8BKPRVQDIOGQWTG-KAVFMPKWSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ParnateTablet, film coated10 mg/1OralCovis Pharmaceuticals, Inc.2013-01-142017-09-30Us
ParnateTablet10 mgOralGlaxosmithkline Inc1992-12-31Not applicableCanada
ParnateTablet, film coated10 mg/1OralConcordia Pharmaceuticals, Inc2013-01-14Not applicableUs
Tranylcypromine SulfateTablet10 mg/1OralRising Pharmaceuticals2012-01-09Not applicableUs
Tranylcypromine SulfateTablet10 mg/1OralRemedy Repack2014-04-012017-12-16Us64980 0183 01 nlmimage10 4b47a5dd
Tranylcypromine SulfateTablet, film coated10 mg/1OralActavis Pharma Company2016-02-05Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tranylcypromine SulfateTablet10 mg/1OralGolden State Medical Supply2012-02-10Not applicableUs
Tranylcypromine SulfateTablet10 mg/1OralPar Pharmaceutical2006-06-30Not applicableUs
International/Other Brands
Jatrosom (Aristo Pharma)
Categories
UNII
3E3V44J4Z9
CAS number
155-09-9
Weight
Average: 133.194
Monoisotopic: 133.089149358
Chemical Formula
C9H11N
InChI Key
AELCINSCMGFISI-UHFFFAOYSA-N
InChI
InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2
IUPAC Name
2-phenylcyclopropan-1-amine
SMILES
NC1CC1C1=CC=CC=C1

Pharmacology

Indication

For the treatment of major depressive episode without melancholia.

Structured Indications
Pharmacodynamics

Tranylcypromine belongs to a class of antidepressants called monoamine oxidase inhibitors (MAOIs). Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor with a rapid onset of activity. MAO is an enzyme that catalyzes the oxidative deamination of a number of amines, including serotonin, norepinephrine, epinephrine, and dopamine. Two isoforms of MAO, A and B, are found in the body. MAO-A is mainly found within cells located in the periphery and catalyzes the breakdown of serotonin, norepinephrine, epinephrine, dopamine and tyramine. MAO-B acts on phenylethylamine, norepinephrine, epinephrine, dopamine and tyramine, is localized extracellularly and is found predominantly in the brain. While the mechanism of MAOIs is still unclear, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. It has been postulated that depression is caused by low levels of serotonin and/or norepinephrine and that increasing serotonergic and norepinephrinergic neurotransmission results in relief of depressive symptoms. MAO A inhibition is thought to be more relevant to antidepressant activity than MAO B inhibition. Selective MAO B inhibitors, such as selegiline, have no antidepressant effects.

Mechanism of action

Tranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.

TargetActionsOrganism
AAmine oxidase [flavin-containing] A
inhibitor
Human
AAmine oxidase [flavin-containing] B
inhibitor
Human
Absorption

Interindividual variability in absorption. May be biphasic in some individuals. Peak plasma concentrations occur in one hour following oral administration with a secondary peak occurring within 2-3 hours. Biphasic absorption may represent different rates of absorption of the stereoisomers of the drug, though additional studies are required to confirm this.

Volume of distribution

1.1-5.7 L/kg

Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life

1.5-3.2 hours in patients with normal renal and hepatic function

Clearance
Not Available
Toxicity

In overdosage, some patients exhibit insomnia, restlessness and anxiety, progressing in severe cases to agitation, mental confusion and incoherence. Hypotension, dizziness, weakness and drowsiness may occur, progressing in severe cases to extreme dizziness and shock. A few patients have displayed hypertension with severe headache and other symptoms. Rare instances have been reported in which hypertension was accompanied by twitching or myoclonic fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing to generalized rigidity and coma.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineTranylcypromine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineTranylcypromine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineTranylcypromine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Tranylcypromine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineTranylcypromine may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcarboseTranylcypromine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololTranylcypromine may increase the hypotensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Tranylcypromine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Tranylcypromine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Tranylcypromine.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Tranylcypromine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Agomelatine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Tranylcypromine.Approved
AlbiglutideTranylcypromine may increase the hypoglycemic activities of Albiglutide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tranylcypromine.Approved, Illicit
AliskirenTranylcypromine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Almotriptan.Approved, Investigational
AlogliptinTranylcypromine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tranylcypromine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Tranylcypromine.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Tranylcypromine.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Tranylcypromine.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Tranylcypromine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amiloride.Approved
AmineptineTranylcypromine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Tranylcypromine.Approved, Withdrawn
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Tranylcypromine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tranylcypromine.Approved
AmlodipineTranylcypromine may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tranylcypromine.Approved, Illicit
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Tranylcypromine.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Tranylcypromine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tranylcypromine.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Tranylcypromine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Tranylcypromine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amyl Nitrite.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Tranylcypromine.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Tranylcypromine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Tranylcypromine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Apraclonidine.Approved
AprepitantThe metabolism of Aprepitant can be decreased when combined with Tranylcypromine.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Tranylcypromine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Arbutamine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Tranylcypromine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Tranylcypromine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tranylcypromine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tranylcypromine.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Tranylcypromine.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Tranylcypromine resulting in a loss in efficacy.Approved
ArticaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tranylcypromine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Tranylcypromine.Approved, Withdrawn
AtenololTranylcypromine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineTranylcypromine may increase the central neurotoxic activities of Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Atorvastatin.Approved
AtropineTranylcypromine may increase the hypertensive activities of Atropine.Approved, Vet Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Tranylcypromine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Azaperone.Vet Approved
AzelastineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Azilsartan medoxomil.Approved
BaclofenThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Baclofen.Approved
BambuterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Tranylcypromine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Tranylcypromine.Approved
BenazeprilTranylcypromine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideTranylcypromine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinTranylcypromine may increase the hypertensive activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Tranylcypromine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Benzocaine.Approved
BenzphetamineTranylcypromine may increase the hypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Tranylcypromine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Tranylcypromine.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Tranylcypromine.Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Tranylcypromine.Approved
BethanidineTranylcypromine may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bezafibrate.Approved
BietaserpineTranylcypromine may increase the hypotensive activities of Bietaserpine.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bifeprunox.Investigational
BimatoprostTranylcypromine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Tranylcypromine.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Tranylcypromine.Approved, Investigational
BosentanTranylcypromine may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Tranylcypromine may increase the hypotensive activities of BQ-123.Investigational
BretyliumTranylcypromine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Tranylcypromine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brimonidine.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Tranylcypromine.Approved, Investigational
BrofaromineTranylcypromine may increase the hypertensive activities of Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tranylcypromine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Tranylcypromine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brotizolam.Approved, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Tranylcypromine.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Tranylcypromine.Approved, Investigational
BupranololTranylcypromine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionTranylcypromine may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tranylcypromine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tranylcypromine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butamben.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tranylcypromine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tranylcypromine.Approved
CadralazineTranylcypromine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineTranylcypromine may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Tranylcypromine.Approved
CanagliflozinTranylcypromine may increase the hypoglycemic activities of Canagliflozin.Approved
Candesartan cilexetilTranylcypromine may increase the hypotensive activities of Candesartan.Approved
CandoxatrilTranylcypromine may increase the hypotensive activities of Candoxatril.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Canertinib.Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Tranylcypromine.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tranylcypromine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tranylcypromine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carfentanil.Illicit, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Tranylcypromine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carisoprodol.Approved
CaroxazoneTranylcypromine may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Tranylcypromine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Tranylcypromine.Approved, Investigational
CeliprololTranylcypromine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Tranylcypromine.Approved, Vet Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Tranylcypromine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Tranylcypromine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Tranylcypromine.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Tranylcypromine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Tranylcypromine.Approved, Vet Approved
ChlorothiazideTranylcypromine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Tranylcypromine.Approved
ChlorphentermineTranylcypromine may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorproethazine.Experimental
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Tranylcypromine.Approved, Vet Approved
ChlorpropamideTranylcypromine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneTranylcypromine may increase the hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Tranylcypromine.Approved
CicletanineTranylcypromine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilTranylcypromine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Tranylcypromine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Tranylcypromine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tranylcypromine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Tranylcypromine.Approved
CirazolineTranylcypromine may increase the hypertensive activities of Cirazoline.Experimental
CisaprideThe metabolism of Cisapride can be decreased when combined with Tranylcypromine.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Tranylcypromine.Approved
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Tranylcypromine.Approved
ClemastineTranylcypromine may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clenbuterol.Approved, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Tranylcypromine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Tranylcypromine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clonazepam.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Tranylcypromine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clopenthixol.Experimental
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Tranylcypromine resulting in a loss in efficacy.Approved, Nutraceutical
CloranololTranylcypromine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tranylcypromine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clothiapine.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Tranylcypromine.Approved, Illicit
ClozapineThe metabolism of Clozapine can be decreased when combined with Tranylcypromine.Approved
CocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Tranylcypromine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Tranylcypromine.Approved, Investigational
CryptenamineTranylcypromine may increase the hypotensive activities of Cryptenamine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Tranylcypromine.Approved
CyclopenthiazideTranylcypromine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Tranylcypromine.Approved, Investigational
CyclothiazideTranylcypromine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineTranylcypromine may increase the anticholinergic activities of Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dantrolene.Approved
DapagliflozinTranylcypromine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tranylcypromine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tranylcypromine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Tranylcypromine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Tranylcypromine.Approved, Investigational
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Tranylcypromine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Tranylcypromine.Approved
DelaprilTranylcypromine may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Tranylcypromine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Deramciclane.Investigational
DeserpidineTranylcypromine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tranylcypromine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Detomidine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Tranylcypromine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dexbrompheniramine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Tranylcypromine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Tranylcypromine.Approved, Illicit, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Tranylcypromine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tranylcypromine.Approved, Vet Approved
DexmethylphenidateTranylcypromine may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Tranylcypromine.Approved, Illicit
DextromethorphanTranylcypromine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tranylcypromine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tranylcypromine.Approved, Illicit, Vet Approved
DiazoxideTranylcypromine may increase the hypotensive activities of Diazoxide.Approved
DibenzepinTranylcypromine may increase the serotonergic activities of Dibenzepin.Experimental
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Tranylcypromine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diclofenamide.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diethyl ether.Experimental
diethylnorspermineTranylcypromine may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionTranylcypromine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Difenoxin.Approved, Illicit
DihydralazineTranylcypromine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Tranylcypromine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Tranylcypromine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Tranylcypromine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Tranylcypromine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tranylcypromine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Tranylcypromine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Tranylcypromine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tranylcypromine.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dipyridamole.Approved
DisopyramideTranylcypromine may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dixyrazine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Tranylcypromine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Tranylcypromine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Tranylcypromine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Doramectin.Vet Approved
DorzolamideTranylcypromine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinTranylcypromine may increase the serotonergic activities of Dosulepin.Approved
DoxapramTranylcypromine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Tranylcypromine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Tranylcypromine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Tranylcypromine.Approved, Investigational
DoxylamineTranylcypromine may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Illicit
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Tranylcypromine.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Drotebanol.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Droxidopa.Approved, Investigational
DulaglutideTranylcypromine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineTranylcypromine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tranylcypromine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Efavirenz.Approved, Investigational
EfonidipineTranylcypromine may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Tranylcypromine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Tranylcypromine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Eltanolone.Investigational
EmpagliflozinTranylcypromine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilTranylcypromine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatTranylcypromine may increase the hypotensive activities of Enalaprilat.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Tranylcypromine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Tranylcypromine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Tranylcypromine.Investigational
EndralazineTranylcypromine may increase the hypotensive activities of Endralazine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tranylcypromine.Approved, Vet Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Tranylcypromine.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Tranylcypromine.Approved, Investigational
EpanololTranylcypromine may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinastineThe metabolism of Epinastine can be decreased when combined with Tranylcypromine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Eplerenone.Approved
EpoprostenolTranylcypromine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanTranylcypromine may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Tranylcypromine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Tranylcypromine.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Tranylcypromine.Investigational
EsmololThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Esmolol.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Tranylcypromine.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tranylcypromine.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Tranylcypromine.Approved, Investigational, Vet Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tranylcypromine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etacrynic acid.Approved
EthanolTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tranylcypromine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Tranylcypromine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tranylcypromine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etoperidone.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Tranylcypromine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Etravirine can be decreased when combined with Tranylcypromine.Approved
ExenatideTranylcypromine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ezogabine.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Tranylcypromine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Felbamate.Approved
FelodipineTranylcypromine may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamTranylcypromine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferulic acidTranylcypromine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tranylcypromine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tranylcypromine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Tranylcypromine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Tranylcypromine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Tranylcypromine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tranylcypromine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tranylcypromine.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Tranylcypromine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tranylcypromine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluspirilene.Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Tranylcypromine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Tranylcypromine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tranylcypromine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Tranylcypromine.Approved, Investigational
FosinoprilTranylcypromine may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Frovatriptan.Approved, Investigational
FurazolidoneTranylcypromine may increase the hypertensive activities of Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tranylcypromine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gabapentin Enacarbil.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Tranylcypromine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tranylcypromine.Approved, Illicit
GefitinibThe metabolism of Gefitinib can be decreased when combined with Tranylcypromine.Approved, Investigational
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Tranylcypromine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gepirone.Investigational
GliclazideTranylcypromine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideTranylcypromine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideTranylcypromine may increase the hypoglycemic activities of Glipizide.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Tranylcypromine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Glutethimide.Approved, Illicit
GlyburideTranylcypromine may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Tranylcypromine.Approved, Investigational
GuanabenzTranylcypromine may increase the hypotensive activities of Guanabenz.Approved
GuanadrelTranylcypromine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineTranylcypromine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineTranylcypromine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Guanfacine.Approved, Investigational
GuanoclorTranylcypromine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTranylcypromine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTranylcypromine may increase the hypotensive activities of Guanoxan.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Tranylcypromine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Tranylcypromine.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Tranylcypromine.Approved, Vet Approved
HarmalineTranylcypromine may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Heroin.Approved, Illicit
HexamethoniumTranylcypromine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hexobarbital.Approved
HydracarbazineTranylcypromine may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazineTranylcypromine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideTranylcypromine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideTranylcypromine may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineTranylcypromine may increase the hypertensive activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Tranylcypromine.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Tranylcypromine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Tranylcypromine.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Tranylcypromine.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Tranylcypromine.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Tranylcypromine.Approved, Investigational
ImatinibThe metabolism of Imatinib can be decreased when combined with Tranylcypromine.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tranylcypromine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tranylcypromine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indalpine.Investigational, Withdrawn
IndapamideTranylcypromine may increase the hypotensive activities of Indapamide.Approved
IndenololTranylcypromine may increase the hypotensive activities of Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indiplon.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Tranylcypromine.Approved, Investigational
IndoraminTranylcypromine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartTranylcypromine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirTranylcypromine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineTranylcypromine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineTranylcypromine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanTranylcypromine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproTranylcypromine may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Tranylcypromine.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Tranylcypromine.Approved
IprindoleTranylcypromine may increase the serotonergic activities of Iprindole.Experimental
IproclozideTranylcypromine may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidTranylcypromine may increase the hypertensive activities of Iproniazid.Withdrawn
IrbesartanTranylcypromine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tranylcypromine.Approved, Vet Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineTranylcypromine may increase the hypotensive activities of Isradipine.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Tranylcypromine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tranylcypromine.Approved, Vet Approved
KetanserinTranylcypromine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketobemidone.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tranylcypromine.Approved, Nutraceutical, Withdrawn
LabetalolThe metabolism of Labetalol can be decreased when combined with Tranylcypromine.Approved
LacidipineTranylcypromine may increase the hypotensive activities of Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lamotrigine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Tranylcypromine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Tranylcypromine.Approved, Investigational
LatanoprostTranylcypromine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineTranylcypromine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Tranylcypromine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levomilnacipran.Approved
LevonordefrinTranylcypromine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tranylcypromine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levosalbutamol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Tranylcypromine.Approved, Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Tranylcypromine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Linezolid.Approved, Investigational
LinsidomineTranylcypromine may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideTranylcypromine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineTranylcypromine may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilTranylcypromine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lofentanil.Illicit
LofepramineTranylcypromine may increase the serotonergic activities of Lofepramine.Experimental
LofexidineTranylcypromine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Tranylcypromine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Tranylcypromine.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Loprazolam.Experimental
LoratadineThe metabolism of Loratadine can be decreased when combined with Tranylcypromine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tranylcypromine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lormetazepam.Approved
LosartanTranylcypromine may increase the hypotensive activities of Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Tranylcypromine.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tranylcypromine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Tranylcypromine.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tranylcypromine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Tranylcypromine.Illicit, Withdrawn
MacitentanThe metabolism of Macitentan can be decreased when combined with Tranylcypromine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Vet Approved
ManidipineTranylcypromine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tranylcypromine.Approved
MebanazineTranylcypromine may increase the hypertensive activities of Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mebicar.Experimental
MecamylamineTranylcypromine may increase the hypotensive activities of Mecamylamine.Approved
MecaserminTranylcypromine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Melperone.Approved
MephedroneTranylcypromine may increase the hypertensive activities of Mephedrone.Investigational
MephentermineTranylcypromine may increase the hypertensive activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Tranylcypromine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tranylcypromine.Approved, Illicit
MequitazineTranylcypromine may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Tranylcypromine.Approved
MetaraminolTranylcypromine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Tranylcypromine.Experimental
MetforminTranylcypromine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Tranylcypromine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tranylcypromine.Approved
MethoserpidineTranylcypromine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineTranylcypromine may increase the hypertensive activities of Methoxamine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Tranylcypromine.Approved, Vet Approved
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Tranylcypromine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methylecgonine.Experimental
Methylene blueTranylcypromine may increase the serotonergic activities of Methylene blue.Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Tranylcypromine.Approved
MethylphenidateTranylcypromine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methylphenobarbital.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Tranylcypromine.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Tranylcypromine.Approved
MetipranololTranylcypromine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metoclopramide.Approved, Investigational
MetolazoneTranylcypromine may increase the hypotensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Tranylcypromine.Approved, Investigational
MetyrosineTranylcypromine may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Tranylcypromine.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Tranylcypromine.Approved
MianserinTranylcypromine may increase the neurotoxic activities of Mianserin.Approved
MibefradilTranylcypromine may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tranylcypromine.Approved, Illicit
MidodrineTranylcypromine may increase the hypertensive activities of Midodrine.Approved
MidomafetamineTranylcypromine may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MifepristoneTranylcypromine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolTranylcypromine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Tranylcypromine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Investigational
MinoxidilTranylcypromine may increase the hypotensive activities of Minoxidil.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Tranylcypromine.Approved
MirtazapineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDATranylcypromine may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Moclobemide.Approved
MoexiprilTranylcypromine may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mosapramine.Experimental
MoxonidineTranylcypromine may increase the hypotensive activities of Moxonidine.Approved
MuzolimineTranylcypromine may increase the hypotensive activities of Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Investigational
NadololTranylcypromine may increase the hypotensive activities of Nadolol.Approved
NaftopidilTranylcypromine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tranylcypromine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Naratriptan.Approved, Investigational
NateglinideTranylcypromine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Tranylcypromine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Tranylcypromine.Approved
NesiritideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nesiritide.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Tranylcypromine.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Tranylcypromine.Approved
NialamideTranylcypromine may increase the hypertensive activities of Nialamide.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Tranylcypromine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Tranylcypromine.Approved
NicorandilNicorandil may increase the hypotensive activities of Tranylcypromine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Tranylcypromine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Tranylcypromine.Approved
NiguldipineTranylcypromine may increase the hypotensive activities of Niguldipine.Experimental
NilutamideThe metabolism of Nilutamide can be decreased when combined with Tranylcypromine.Approved
NilvadipineTranylcypromine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineTranylcypromine may increase the hypotensive activities of Nimodipine.Approved
NisoldipineTranylcypromine may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tranylcypromine.Approved
NitrendipineTranylcypromine may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tranylcypromine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Tranylcypromine.Approved, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nitroglycerin.Approved, Investigational
NitroprussideTranylcypromine may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tranylcypromine.Approved, Vet Approved
NorepinephrineTranylcypromine may increase the hypertensive activities of Norepinephrine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tranylcypromine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tranylcypromine.Approved
OctamoxinTranylcypromine may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Tranylcypromine.Approved, Investigational
OlmesartanTranylcypromine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olopatadine.Approved
OmapatrilatTranylcypromine may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Tranylcypromine.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Tranylcypromine.Approved
OpipramolTranylcypromine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Orciprenaline.Approved
OrphenadrineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Osanetant.Investigational
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Tranylcypromine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tranylcypromine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxethazaine.Investigational
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Tranylcypromine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tranylcypromine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxypertine.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tranylcypromine.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tranylcypromine.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Tranylcypromine.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Tranylcypromine.Approved
PapaverineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Papaverine.Approved
ParaldehydeTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineTranylcypromine may increase the hypotensive activities of Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tranylcypromine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Tranylcypromine.Approved
PenbutololTranylcypromine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Penfluridol.Experimental
PentamidineTranylcypromine may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tranylcypromine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tranylcypromine.Approved, Vet Approved
PentoliniumTranylcypromine may increase the hypotensive activities of Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
PerazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perazine.Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Tranylcypromine.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Tranylcypromine.Approved
PerindoprilTranylcypromine may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Tranylcypromine.Approved
PethidineTranylcypromine may increase the serotonergic activities of Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Tranylcypromine.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenelzine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Tranylcypromine.Approved, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenibut.Experimental
PheniprazineTranylcypromine may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tranylcypromine.Approved
PhenoxybenzamineTranylcypromine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenoxyethanol.Approved
PhenoxypropazineTranylcypromine may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineTranylcypromine may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineTranylcypromine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineTranylcypromine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenytoin.Approved, Vet Approved
PholcodinePholcodine may increase the serotonergic activities of Tranylcypromine.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Tranylcypromine.Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tranylcypromine.Approved
PinacidilTranylcypromine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe metabolism of Pindolol can be decreased when combined with Tranylcypromine.Approved
PioglitazoneTranylcypromine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Tranylcypromine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Tranylcypromine.Approved
PirbuterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Piritramide.Investigational
PirlindoleTranylcypromine may increase the hypertensive activities of Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Tranylcypromine.Approved
PivhydrazineTranylcypromine may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenTranylcypromine may increase the anticholinergic activities of Pizotifen.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Tranylcypromine.Approved
PolythiazideTranylcypromine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Tranylcypromine.Approved
PramipexoleTranylcypromine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideTranylcypromine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pramocaine.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Tranylcypromine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Tranylcypromine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prazepam.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Tranylcypromine.Approved, Vet Approved
PrazosinTranylcypromine may increase the hypotensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tranylcypromine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tranylcypromine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Primidone.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Tranylcypromine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tranylcypromine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Tranylcypromine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Procaterol.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Tranylcypromine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Tranylcypromine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Tranylcypromine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tranylcypromine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Promethazine.Approved
PropafenoneThe serum concentration of Tranylcypromine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propericiazine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Tranylcypromine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propoxycaine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Tranylcypromine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tranylcypromine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Proxibarbal.Experimental
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Tranylcypromine.Investigational
PSD502The risk or severity of adverse effects can be increased when Tranylcypromine is combined with PSD502.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Tranylcypromine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tranylcypromine.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Tranylcypromine.Approved
QuinaprilTranylcypromine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineTranylcypromine may increase the hypoglycemic activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Quinisocaine.Experimental
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Tranylcypromine.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ramelteon.Approved, Investigational
RamiprilTranylcypromine may increase the hypotensive activities of Ramipril.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Tranylcypromine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tranylcypromine.Approved
RemikirenTranylcypromine may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Tranylcypromine.Approved, Withdrawn
RepaglinideTranylcypromine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Tranylcypromine.Investigational
RescinnamineTranylcypromine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Reserpine.Approved
RilmenidineTranylcypromine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatTranylcypromine may increase the hypotensive activities of Riociguat.Approved
RisperidoneTranylcypromine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ritanserin.Investigational
RitobegronTranylcypromine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ritodrine.Approved
RitonavirThe metabolism of Ritonavir can be decreased when combined with Tranylcypromine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Rizatriptan.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Tranylcypromine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Romifidine.Vet Approved
RopiniroleTranylcypromine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Tranylcypromine.Approved
RosiglitazoneTranylcypromine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Tranylcypromine.Approved
RotigotineTranylcypromine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Tranylcypromine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tranylcypromine.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Tranylcypromine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tranylcypromine.Approved
SafrazineTranylcypromine may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salmeterol.Approved
SaprisartanTranylcypromine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Tranylcypromine.Approved, Investigational
SaxagliptinTranylcypromine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tranylcypromine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagTranylcypromine may increase the hypotensive activities of Selexipag.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sepranolone.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Tranylcypromine.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Tranylcypromine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tranylcypromine.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Tranylcypromine.Approved, Investigational
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Tranylcypromine.Approved
SitagliptinTranylcypromine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanTranylcypromine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Tranylcypromine.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
SotalolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Tranylcypromine.Experimental
SpiraprilTranylcypromine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Tranylcypromine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tranylcypromine.Approved, Investigational
SulfadiazineTranylcypromine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleTranylcypromine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleTranylcypromine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tranylcypromine.Approved
SultoprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Tranylcypromine.Approved, Investigational
SunitinibTranylcypromine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TalinololTranylcypromine may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Tranylcypromine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Tranylcypromine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tasimelteon.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Tranylcypromine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Tranylcypromine.Investigational, Withdrawn
TelmisartanTranylcypromine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tranylcypromine.Approved
TemocaprilTranylcypromine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TeniposideThe metabolism of Teniposide can be decreased when combined with Tranylcypromine.Approved
TerazosinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Tranylcypromine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Tranylcypromine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Tranylcypromine.Experimental
TerlipressinTranylcypromine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Tranylcypromine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Tranylcypromine.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Tranylcypromine.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tranylcypromine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetrodotoxin.Investigational
TetryzolineTranylcypromine may increase the hypertensive activities of Tetryzoline.Approved
ThalidomideTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineTranylcypromine may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Tranylcypromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tranylcypromine.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Tranylcypromine.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tranylcypromine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiagabine.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Tranylcypromine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiapride.Approved, Investigational
TiboloneTranylcypromine may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Tranylcypromine.Approved
TicrynafenTranylcypromine may increase the hypotensive activities of Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiletamine.Vet Approved
TimololThe metabolism of Timolol can be decreased when combined with Tranylcypromine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Tranylcypromine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Tranylcypromine.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tizanidine.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Tranylcypromine.Approved, Investigational
TolazamideTranylcypromine may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTranylcypromine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideTranylcypromine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tranylcypromine.Approved, Withdrawn
TolonidineTranylcypromine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneTranylcypromine may increase the hypertensive activities of Toloxatone.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Tranylcypromine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Topiramate.Approved
TorasemideTranylcypromine may increase the hypotensive activities of Torasemide.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Tranylcypromine.Approved, Investigational
TramadolTramadol may increase the neuroexcitatory activities of Tranylcypromine.Approved, Investigational
TrandolaprilTranylcypromine may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TravoprostTranylcypromine may increase the hypotensive activities of Travoprost.Approved
TreprostinilTranylcypromine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tranylcypromine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideTranylcypromine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tranylcypromine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tranylcypromine.Approved, Vet Approved
TrimazosinTranylcypromine may increase the hypotensive activities of Trimazosin.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Tranylcypromine.Approved
TrimethaphanTranylcypromine may increase the hypotensive activities of Trimethaphan.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tranylcypromine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triprolidine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Tranylcypromine.Withdrawn
TropisetronTropisetron may increase the serotonergic activities of Tranylcypromine.Approved, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Tranylcypromine.Experimental
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Tranylcypromine.Approved
UnoprostoneTranylcypromine may increase the hypotensive activities of Unoprostone.Approved
UrapidilTranylcypromine may increase the hypotensive activities of Urapidil.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Tranylcypromine.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tranylcypromine.Approved, Investigational
ValsartanTranylcypromine may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Tranylcypromine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Veralipride.Experimental
VerapamilThe metabolism of Verapamil can be decreased when combined with Tranylcypromine.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Tranylcypromine.Approved, Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vigabatrin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vilazodone.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Tranylcypromine.Approved
VincamineTranylcypromine may increase the hypotensive activities of Vincamine.Experimental
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Tranylcypromine.Approved, Investigational
VinpocetineTranylcypromine may increase the hypotensive activities of Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Tranylcypromine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vortioxetine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Tranylcypromine.Approved
XenonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Xenon.Experimental
XipamideTranylcypromine may increase the hypotensive activities of Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Xylazine.Vet Approved
XylometazolineTranylcypromine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineThe therapeutic efficacy of Tranylcypromine can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Tranylcypromine.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tranylcypromine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Tranylcypromine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tranylcypromine.Approved
ZofenoprilTranylcypromine may increase the hypotensive activities of Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tranylcypromine.Approved, Investigational
ZolpidemTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tranylcypromine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zotepine.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Tranylcypromine.Approved, Investigational
Food Interactions
  • Avoid aged foods (chesse, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid St. John's Wort.

References

General References
  1. Frieling H, Bleich S: Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73. [PubMed:16927039]
  2. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774]
External Links
KEGG Drug
D08625
KEGG Compound
C07155
ChemSpider
5329
BindingDB
50113851
ChEBI
131512
ChEMBL
CHEMBL313833
Therapeutic Targets Database
DAP000081
PharmGKB
PA451741
HET
GJZ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Tranylcypromine
ATC Codes
N06AF04 — Tranylcypromine
AHFS Codes
  • 28:16.04.12 — Monoamine Oxidase Inhibitors
FDA label
Download (152 KB)
MSDS
Download (38.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedNot AvailableTo Determine the Bioavailability of Tranylcypromine1
1RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Leukemias / Myelodysplastic Syndromes1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
3Not Yet RecruitingTreatmentIntracerebral Hemorrhage / Stroke Hemorrhagic1
3RecruitingTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentAcute Upper Gastrointestinal Hemorrhage1
4CompletedPreventionOsteoarthritis of the Knees1
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentDepressive State1
4CompletedTreatmentHaemorrhage1
4Not Yet RecruitingPreventionOsteoarthritis of the Knees2
4TerminatedTreatmentMajor Depressive Disorder (MDD)2
4Unknown StatusTreatmentBipolar Disorder I or II1
Not AvailableCompletedTreatmentBipolar Disorder (BD)1
Not AvailableCompletedTreatmentBlood Loss / Congenital Heart Disease (CHD)1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Par pharmaceutical inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
Tablet, film coatedOral10 mg/1
TabletOral10 mg/1
Prices
Unit descriptionCostUnit
Parnate 10 mg tablet1.64USD tablet
Tranylcypromine Sulfate 10 mg tablet1.3USD tablet
Tranylcypromine sulf 10 mg tablet1.25USD tablet
Parnate 10 mg Tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)79-80 °C at 1.50E+00 mm HgNot Available
water solubility4.86E+004 mg/LNot Available
logP1.58HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility1.49 mg/mLALOGPS
logP1.5ALOGPS
logP1.34ChemAxon
logS-2ALOGPS
pKa (Strongest Basic)9.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity41.7 m3·mol-1ChemAxon
Polarizability15.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9383
Caco-2 permeable+0.7935
P-glycoprotein substrateNon-substrate0.8349
P-glycoprotein inhibitor INon-inhibitor0.9566
P-glycoprotein inhibitor IINon-inhibitor0.9899
Renal organic cation transporterNon-inhibitor0.8659
CYP450 2C9 substrateNon-substrate0.8439
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7604
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.8659
CYP450 2D6 inhibitorNon-inhibitor0.7879
CYP450 2C19 inhibitorInhibitor0.8748
CYP450 3A4 inhibitorNon-inhibitor0.9372
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6942
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6686
BiodegradationReady biodegradable0.5525
Rat acute toxicity2.4266 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9807
hERG inhibition (predictor II)Non-inhibitor0.9378
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Benzene and substituted derivatives / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
Aralkylamine / Benzenoid / Monocyclic benzene moiety / Organopnictogen compound / Hydrocarbon derivative / Primary amine / Primary aliphatic amine / Aromatic homomonocyclic compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163]
  3. Shioda K, Nisijima K, Yoshino T, Kato S: Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett. 2010 Oct 4;482(3):216-9. doi: 10.1016/j.neulet.2010.07.039. Epub 2010 Jul 23. [PubMed:20655983]
  4. Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol. 2006 Mar;17(2):151-9. [PubMed:16495723]
  5. Lang W, Masucci JA, Caldwell GW, Hageman W, Hall J, Jones WJ, Rafferty BM: Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Anal Biochem. 2004 Oct 1;333(1):79-87. [PubMed:15351283]
  6. Shioda K, Nisijima K, Yoshino T, Kato S: Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):633-40. [PubMed:15276688]
  7. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511]
  8. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774]
  9. Cohen C, Curet O, Perrault G, Sanger DJ: Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav. 1999 Nov;64(3):535-9. [PubMed:10548268]
  10. Wiest SA, Steinberg MI: 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):209-16. [PubMed:10494892]
  11. Loscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92. [PubMed:10027835]
  12. Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. [PubMed:8749840]
  13. Finberg JP, Youdim MB: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002 Dec;43(7):1110-8. [PubMed:12504917]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163]
  3. Shioda K, Nisijima K, Yoshino T, Kato S: Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett. 2010 Oct 4;482(3):216-9. doi: 10.1016/j.neulet.2010.07.039. Epub 2010 Jul 23. [PubMed:20655983]
  4. Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol. 2006 Mar;17(2):151-9. [PubMed:16495723]
  5. Lang W, Masucci JA, Caldwell GW, Hageman W, Hall J, Jones WJ, Rafferty BM: Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Anal Biochem. 2004 Oct 1;333(1):79-87. [PubMed:15351283]
  6. Shioda K, Nisijima K, Yoshino T, Kato S: Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):633-40. [PubMed:15276688]
  7. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511]
  8. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774]
  9. Cohen C, Curet O, Perrault G, Sanger DJ: Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav. 1999 Nov;64(3):535-9. [PubMed:10548268]
  10. Wiest SA, Steinberg MI: 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):209-16. [PubMed:10494892]
  11. Loscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92. [PubMed:10027835]
  12. Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. [PubMed:8749840]
  13. Finberg JP, Youdim MB: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002 Dec;43(7):1110-8. [PubMed:12504917]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
4. Cytochrome P450 2C19
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Stadel R, Yang J, Nalwalk JW, Phillips JG, Hough LB: High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain. Drug Metab Dispos. 2008 Mar;36(3):614-21. Epub 2007 Dec 19. [PubMed:18094038]
  2. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:25